Table 1.
Baseline characteristics of RA patients.
| RA Patients | N = 280 |
| Demographics | |
| Sex (females/males (% of females)) | 220/60 (78.6%) |
| Age (years) (mean (±SD)) | 51.6 (±12.3) |
| Current smokers (%) | 33.3% |
| Clinical data | |
| Disease duration (years) (mean (±SD)) | 12.6 (±8.1) |
| Disease onset (years) (mean (±SD)) | 39.2 (±12.0) |
| DAS28 at baseline (mean (±SD)) | 6.5 (±0.6) |
| CRP at baseline (mean (±SD)) | 24.4 (±35.7) |
| RF-positive (%) | 65.9% |
| anti-CCP+ (%) | 95.4% |
| Anti-TNF drugs | |
| Etanercept | 54% |
| Adalimumab | 33% |
| Infliximab | 7% |
| Certolizumab pegol | 6% |
| Concomitant treatment | |
| Glucocorticosteroids | 91% |
| Methotrexate | 92% |
RA: rheumatoid arthritis; DAS28: disease activity score 28; CRP: C-reactive protein; RF: rheumatoid factor; anti-CCP: anti-cyclic citrullinated peptide antibodies; SD: standard deviation; percentages calculated in regard to a total number of patients.